| Platinum-based chemotherapy plus cetuximab in head and neck cancer JB Vermorken, R Mesia, F Rivera, E Remenar, A Kawecki, S Rottey, ... New England Journal of Medicine 359 (11), 1116-1127, 2008 | 4188 | 2008 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 3068 | 2019 |
| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 2992 | 2019 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial R Pirker, JR Pereira, A Szczesna, J von Pawel, M Krzakowski, R Ramlau, ... The Lancet 373 (9674), 1525-1531, 2009 | 1833 | 2009 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1681 | 2019 |
| Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial E Felip, N Altorki, C Zhou, T Csőszi, I Vynnychenko, O Goloborodko, ... The Lancet 398 (10308), 1344-1357, 2021 | 1038 | 2021 |
| Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non … MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, ... Journal of Clinical Oncology 30 (17), 2055-2062, 2012 | 886 | 2012 |
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial JA Ajani, W Rodriguez, G Bodoky, V Moiseyenko, M Lichinitser, ... Journal of clinical oncology 28 (9), 1547-1553, 2010 | 732 | 2010 |
| Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open … T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ... The Lancet Oncology 21 (12), 1563-1573, 2020 | 651 | 2020 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 488 | 2021 |
| Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial R Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, ... Journal of Thoracic Oncology 15 (8), 1351-1360, 2020 | 486 | 2020 |
| FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18. 2-positive gastric and gastro-oesophageal … U Sahin, Ö Türeci, G Manikhas, F Lordick, A Rusyn, I Vynnychenko, ... Annals of oncology 32 (5), 609-619, 2021 | 317 | 2021 |
| Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study RL Ferris, R Haddad, C Even, M Tahara, M Dvorkin, TE Ciuleanu, ... Annals of Oncology 31 (7), 942-950, 2020 | 313 | 2020 |
| IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab+ carboplatin+ paclitaxel or nab-paclitaxel vs carboplatin+ nab-paclitaxel as 1L … RM Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, DR Abreu, ... J clin oncol 36 (18 suppl), LBA9000, 2018 | 272 | 2018 |
| International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non–small-cell lung … GV Scagliotti, I Vynnychenko, K Park, Y Ichinose, K Kubota, F Blackhall, ... Journal of Clinical Oncology 30 (23), 2829-2836, 2012 | 209 | 2012 |
| Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–positive metastatic breast cancer: a randomized … HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, ... Jama 317 (1), 37-47, 2017 | 174 | 2017 |
| First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data … U Gatzemeier, J Von Pawel, I Vynnychenko, P Zatloukal, F De Marinis, ... The lancet oncology 12 (1), 30-37, 2011 | 139 | 2011 |
| IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung … HA Wakelee, NK Altorki, C Zhou, T Csőszi, IO Vynnychenko, ... Journal of Clinical Oncology 39 (15_suppl), 8500-8500, 2021 | 136 | 2021 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of … BI Rini, ER Plimack, V Stus, T Waddell, R Gafanov, F Pouliot, D Nosov, ... Journal of Clinical Oncology 39 (15_suppl), 4500-4500, 2021 | 130 | 2021 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor … BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... Journal of Clinical Oncology 37 (15_suppl), 4500-4500, 2019 | 130 | 2019 |
